SidaGhanaV1, Main, Exploration, bibRecord, 000042

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Identifieur interne : 000042 ( Main/Exploration ); précédent : 000041; suivant : 000043

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Auteurs : Raymond A. Tetteh [Pays-Bas] ; Barbara A. Yankey [États-Unis] ; Edmund T. Nartey [Ghana] ; Margaret Lartey [Ghana] ; Hubert G M. Leufkens [Pays-Bas] ; Alexander N O. Dodoo [Ghana]

Source :

Drug safety [ 1179-1942 ] ; 2017.

RBID : pubmed:28130774

Abstract

Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www.clinicaltrials.gov " and scholar.google, using combination search terms 'pre-exposure prophylaxis', 'safety concerns in the use of pre-exposure prophylaxis', 'truvada use as PrEP', 'guidelines for PrEP use', 'HIV pre-exposure prophylaxis' and 'tenofovir' to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.

DOI: 10.1007/s40264-017-0505-6
PubMed: 28130774

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.</title>
<author><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name>
<affiliation wicri:level="4"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Public Heath, Georgia State University, Atlanta, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Public Heath, Georgia State University, Atlanta, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name>
<affiliation wicri:level="4"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<orgName type="university">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<orgName type="university">Université du Ghana</orgName>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
<orgName type="university" n="3">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name>
<affiliation wicri:level="4"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name>
<affiliation wicri:level="4"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<orgName type="university">Université du Ghana</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28130774</idno>
<idno type="pmid">28130774</idno>
<idno type="doi">10.1007/s40264-017-0505-6</idno>
<idno type="wicri:Area/PubMed/Corpus">000574</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000574</idno>
<idno type="wicri:Area/PubMed/Curation">000574</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000574</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000574</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000574</idno>
<idno type="wicri:Area/Ncbi/Merge">000A74</idno>
<idno type="wicri:Area/Ncbi/Curation">000A74</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A74</idno>
<idno type="wicri:Area/Main/Merge">000042</idno>
<idno type="wicri:Area/Main/Curation">000042</idno>
<idno type="wicri:Area/Main/Exploration">000042</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.</title>
<author><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name>
<affiliation wicri:level="4"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. r_niiatetteh@yahoo.com.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Public Heath, Georgia State University, Atlanta, GA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Public Heath, Georgia State University, Atlanta, GA</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name>
<affiliation wicri:level="4"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<orgName type="university">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>Department of Medicine, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<orgName type="university">Université du Ghana</orgName>
<placeName><settlement type="city">Accra</settlement>
<settlement type="town">Legon (Ghana)</settlement>
<region type="region">Région du Grand Accra</region>
</placeName>
<orgName type="university" n="3">Université du Ghana</orgName>
</affiliation>
</author>
<author><name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name>
<affiliation wicri:level="4"><nlm:affiliation>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
<orgName type="university">Université d'Utrecht</orgName>
</affiliation>
</author>
<author><name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name>
<affiliation wicri:level="4"><nlm:affiliation>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra, Ghana.</nlm:affiliation>
<country xml:lang="fr">Ghana</country>
<wicri:regionArea>World Health Organization Collaborating Centre for Advocacy and Training in Pharmacovigilance, Centre for Tropical Clinical Pharmacology and Therapeutics, School of Medicine and Dentistry, University of Ghana, Legon, Accra</wicri:regionArea>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
<orgName type="university">Université du Ghana</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Drug safety</title>
<idno type="eISSN">1179-1942</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Available evidence supports the efficacy of pre-exposure prophylaxis (PrEP) in decreasing the incidence of human immunodeficiency virus (HIV) infection among high-risk individuals, especially when used in combination with other behavioural preventive methods. Safety concerns about PrEP present challenges in the implementation and use of PrEP. The aim of this review is to discuss safety concerns observed in completed clinical trials on the use of PrEP. We performed a literature search on PrEP in PubMed, global advocacy for HIV prevention (Aids Vaccine Advocacy Coalition) database, clinical trials registry " http://www.clinicaltrials.gov " and scholar.google, using combination search terms 'pre-exposure prophylaxis', 'safety concerns in the use of pre-exposure prophylaxis', 'truvada use as PrEP', 'guidelines for PrEP use', 'HIV pre-exposure prophylaxis' and 'tenofovir' to identify clinical trials and literature on PrEP. We present findings associated with safety issues on the use of PrEP based on a review of 11 clinical trials on PrEP with results on safety and efficacy as at April 2016. We also reviewed findings from routine real-life practice reports. The pharmacological intervention for PrEP was tenofovir disoproxil fumarate/emtricitabine in a combined form as Truvada(®) or tenofovir as a single entity. Both products are efficacious for PrEP and seem to have a good safety profile. Regular monitoring is recommended to prevent long-term toxic effects. The main adverse effects observed with PrEP are gastrointestinal related; basically mild to moderate nausea, vomiting and diarrhea. Other adverse drug effects worth monitoring are liver enzymes, renal function and bone mineral density. PrEP as an intervention to reduce HIV transmission appears to have a safe benefit-risk profile in clinical trials. It is recommended for widespread use but adherence monitoring and real-world safety surveillance are critical in the post-marketing phase to ensure that the benefits observed in clinical trials are maintained in real-world use.</div>
</front>
</TEI>
<affiliations><list><country><li>Ghana</li>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region><li>Géorgie (États-Unis)</li>
<li>Région du Grand Accra</li>
<li>Utrecht (province)</li>
</region>
<settlement><li>Accra</li>
<li>Legon (Ghana)</li>
<li>Utrecht</li>
</settlement>
<orgName><li>Université d'Utrecht</li>
<li>Université du Ghana</li>
</orgName>
</list>
<tree><country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Tetteh, Raymond A" sort="Tetteh, Raymond A" uniqKey="Tetteh R" first="Raymond A" last="Tetteh">Raymond A. Tetteh</name>
</region>
<name sortKey="Leufkens, Hubert G M" sort="Leufkens, Hubert G M" uniqKey="Leufkens H" first="Hubert G M" last="Leufkens">Hubert G M. Leufkens</name>
</country>
<country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Yankey, Barbara A" sort="Yankey, Barbara A" uniqKey="Yankey B" first="Barbara A" last="Yankey">Barbara A. Yankey</name>
</region>
</country>
<country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Nartey, Edmund T" sort="Nartey, Edmund T" uniqKey="Nartey E" first="Edmund T" last="Nartey">Edmund T. Nartey</name>
</region>
<name sortKey="Dodoo, Alexander N O" sort="Dodoo, Alexander N O" uniqKey="Dodoo A" first="Alexander N O" last="Dodoo">Alexander N O. Dodoo</name>
<name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000042 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000042 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28130774
   |texte=   Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28130774" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaGhanaV1

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

Le SIDA au Ghana (serveur d'exploration)

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.